NicOx, extension of ophthalmology agreement with Pfizer

January 8, 2008. Sophia Antipolis, France - NicOx S.A. (Euronext Paris: COX) today announced it has signed an extension of its March 2006 collaboration agreement, which grants Pfizer Inc the exclusive right to apply its proprietary nitric oxide-donating technology to drug discovery research
in the field of ophthalmology. This one-year extension of the research phase of the agreement will result in NicOx receiving €3 million in research funding in March 2008 and prolongs Pfizer’s option to license resulting compounds until May 2009... [PDF] NicOx' Press Release - PDF du Communiqué de Presse de NicOx-

Transgene's Therapeutic Vaccine TG4010, Phase IIb Data in Advanced Non-Small Cell Lung Cancer

January 10, 2008 - Transgene(Euronext Paris: FR0005175080) announces promising preliminary data from the Phase IIb trial evaluating its therapeutic vaccine TG4010 (MVA-MUC1-IL2) as an adjunct to first line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)... [PDF] Transgene's Press Release - PDF du communiqué de presse de Transgene, en français-

Iris Pharma and Clirophtha merger, unique ophthalmology CRO

Nice (France), 8 January 2008 – Iris Pharma of France, a specialist contract research organisation (CRO) for pre-clinical research in ophthalmology, has announced the completion of its merger with Clirophtha, a unique CRO in Europe and North America that is completely dedicated to ophthalmology clinical trials. The new entity will be known as Iris Pharma... Iris' Press Release -

BT PHARMA, development of therapeutic cancer vaccines with the Institut Pasteur

Toulouse, 11 January 2008 - The Institut Pasteur has agreed to add a new patent under the exclusive license granted to BT PHARMA with regards to the Adenylate Cyclase vector technology. This patent has been filed in all major markets of the OECD as well as in China and India.
The patent claims a novel combination cancer treatment, which associates a chemotherapeutic agent with an immunotherapeutic agent, resulting in a dramatically improved specific immune response against the malignant tissues. In fact, the treatment induces simultaneously an adaptive cellular immune response (tumour cell specific), an amplified innate immune response and decreases the immune tolerance that tumours typically acquire. This patented combination has, for the first time in appropriate animal models, allowed to totally eliminate very large vascularized solid tumours... BT PHARMA's Press Release [PDF] -

Aureus Pharma's AurSCOPE Ion Channel licenses to Neuromed Pharmaceuticals

Paris, FRANCE, December 11, 2007 - Aureus Pharma a leading provider of knowledge management solutions to accelerate discovery in the life sciences industry, announces that Neuromed Pharmaceuticals, a biopharmaceutical company developing new and improved chronic pain drugs has licensed the AurSCOPE Ion Channel Knowledge database... Aureus ' Press Release-

Merck Serono and Flamel to Collaborate on an Extended Release Formulation for Therapeutic Proteins

Lyon, France, December 20, 2007 Flamel Technologies (NASDAQ:FLML) announced that it has entered into a collaboration with Merck Serono, a division of Merck KGaA, to investigate the applicability of Flamel's Medusa® technology for the extended release of a therapeutic protein of Merck Serono's portfolio... english : Flamel's press Release - french : Merck Serono's Press Release [PDF] -